Skip to main content

Table 1 Patient characteristics

From: Effect of a selective neutrophil elastase inhibitor on mortality and ventilator-free days in patients with increased extravascular lung water: a post hoc analysis of the PiCCO Pulmonary Edema Study

Patient characteristic

Unadjusted groups

IPTW Groups

Matched groups

Sivelestat (n  = 87)

Control (n  = 77)

Standardized difference

Sivelestat (n  = 162)

Control (n  = 167)

Standardized difference

Sivelestat (n  = 31)

Control (n  = 31)

Standardized difference

Age, year

66.1 (17.5)

65.9 (16.2)

0.01

67.7 (16.2)

69.0 (15.8)

−0.08

69.8 (15.6)

67.3 (15.3)

0.16

Male sex

57 (65.5)

50 (64.9)

0.01

104 (64.2)

114 (68.3)

−0.09

21 (67.7)

19 (61.3)

0.13

Academic hospital

49 (56.3)

48 (63.3)

−0.14

92 (56.8)

86 (51.8)

0.10

20 (64.5)

15 (48.4)

0.33

Hospital volume (cases)

         

 Low (1–10)

37 (42.5)

43 (55.8)

−0.27

73 (45.1)

70 (41.9)

0.06

15 (48.4)

14 (45.2)

0.06

 Medium (11–20)

19 (21.8)

18 (23.4)

−0.04

32 (19.8)

34 (20.4)

−0.01

8 (25.8)

5 (16.1)

0.28

 High (≥21)

31 (35.6)

16 (20.8)

0.33

57 (35.2)

63 (37.7)

−0.05

8 (25.8)

12 (38.7)

−0.28

Direct lung injury

54 (62.1)

44 (57.1)

0.10

94 (58.4)

104 (62.3)

−0.08

19 (61.3)

21 (67.7)

−0.13

APACHE II

22.2 (7.4)

23.5 (7.4)

−0.18

23.5 (7.3)

23.3 (7.5)

0.03

23.7 (5.5)

24.0 (7.6)

−0.05

SOFA score

10.1 (3.3)

11.2 (3.6)

−0.32

10.7 (3.3)

10.6 (3.7)

0.03

10.8 (3.3)

10.0 (3.2)

0.25

SIRS score

2.3 (1.0)

2.4 (1.2)

−0.09

2.4 (1.1)

2.4 (1.1)

0.00

2.4 (1.2)

2.5 (1.1)

−0.09

MAP, mmHg

75.5 (18.3)

77.2 (15.5)

−0.10

77.3 (19.1)

78.8 (17.2)

−0.08

75.8 (20.1)

73.9 (14.3)

0.11

CVP, mmHg

10.7 (5.4)

9.3 (5.2)

0.26

9.8 (5.2)

9.7 (5.1)

0.02

10.5 (4.7)

9.5 (5.8)

0.19

Fluid balance on Day 0, mL

2,239 (2,228)

1,498 (1,640)

0.38

1,915 (1,977)

1,861 (1,686)

0.03

1,495 (2,267)

1,673 (2,333)

−0.08

PaO2/FiO2

148.5 (73.1)

148.4 (65.6)

0

142.9 (70.2)

145.6 (63.9)

−0.04

141.7 (71.1)

128.5 (60.2)

0.20

PEEP, cm/H2O

8.4 (4.9)

8.3 (4.1)

0.02

8.2 (4.6)

8.1 (3.8)

0.02

8.1 (5.0)

8.8 (4.6)

−0.15

Cardiac index, L/m2

3.5 (1.4)

3.5 (1.2)

0

3.4 (1.4)

3.4 (1.1)

0.00

3.7 (1.5)

3.2 (1.0)

0.39

GEDI, mL/m2

836.9 (236.4)

784.2 (158.0)

0.26

809.9 (208.4)

805.2 (149.3)

0.03

805.9 (167.5)

761.9 (150.1)

0.28

EVLWi, mL/kg

20.0 (7.1)

17.2 (6.4)

0.41

19.1 (6.4)

19.4 (7.6)

−0.04

17.1 (6.2)

18.5 (7.1)

−0.21

PVPI

3.5 (1.5)

3.1 (1.2)

0.29

3.3 (1.3)

3.4 (1.3)

−0.08

3.0 (0.98)

3.5 (1.5)

−0.39

Corticosteroid use

38 (43.7)

26 (33.8)

0.20

62 (38.3)

69 (41.3)

−0.06

12 (41.9)

10 (32.3)

0.20

Catecholamine use

58 (66.7)

59 (76.6)

−0.22

117 (72.2)

113 (67.7)

0.10

23 (74.2)

23 (74.2)

0.00

Renal replacement therapy

25 (28.7)

18 (23.4)

0.12

45 (27.8)

50 (30.1)

−0.05

9 (29.0)

6 (19.4)

0.23

Diuretic use

43 (49.4)

38 (49.4)

0.00

75 (46.6)

84 (50.3)

−0.07

16 (51.6)

13 (41.9)

0.20

PMX use

12 (13.8)

6 (7.6)

0.20

18 (11.1)

14 (8.4)

0.09

4 (12.9)

1 (3.2)

0.36

  1. Number of patients (n) in the IPTW groups was an estimated number determined by weighting inversed probability (propensity score).
  2. APACHE, acute physiology and chronic health evaluation, CVP, central venous pressure, EVLWi, extravascular lung water index, GEDI, global end-diastolic volume index, IPTW, inverse probability of treatment weighting, PEEP, positive end-expiratory pressure, PMX, polymyxin B hemoperfusion, PVPI, pulmonary vascular permeability index, SIRS, systemic inflammatory response syndrome, SOFA, sequential organ failure assessment.